Iovance飙升17%，2024年和2025年收入指引远高于共识

2024-08-09 21:29

Iovance Biotherapeutics is up ~17% in premarket trading Friday after announcing 2024 and 2025 revenue outlook ranges that were both significantly above the consensus estimates.
For 2024, the company expects revenue of $160M-$165M. Consensus is $140.78M. In 2025, revenue is projected at $450M-$475M. Consensus is $395.34M.
Iovance attributes the substantial revenue growth to T-cell melanoma therapy Amtagvi (lifileucel), which was approved by the U.S. FDA in February.
Lifileucel is pending a regulatory decision by the European Medicines Agency. Additional applications to regulations in the U.K. and Canada are expected by the end of the year, with Australia in H1 2025.
In Q2, the company beat on both lines.
In the quarter, Iovance's net loss narrowed 9% year over year to $97.1M (-$0.34 basic and diluted vs. -$0.47).

More on Iovance Biotherapeutics